$EXAS Exact Sciences

Exact Sciences seems to be holding its own with some strong support at the $10 level. The company states that it is still on track with its clinical trial and the 4Q12 or 1Q13 FDA submittal is still on track. Like a broken record, no news is good news and I’m happy to hear very little from the FDA so far.

Sentiment: I may suggest a sell at 12 if it reaches this mark before the end of the year. I do feel positive about the future prospects of this company, but it feel if it reaches 12 it may be a little expensive and we may be able to sell and buy back lower.

Leave a Comment